147 related articles for article (PubMed ID: 38065892)
21. Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy.
Domblides C; Gross-Goupil M; Ravaud A; Poullenot F; Daste A
Immunotherapy; 2021 Jun; 13(9):741-744. PubMed ID: 33906378
[TBL] [Abstract][Full Text] [Related]
22. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
[TBL] [Abstract][Full Text] [Related]
23. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event.
Yamauchi Y; Arai M; Akizue N; Ohta Y; Okimoto K; Matsumura T; Fan MM; Imai C; Tawada A; Kato J; Kato N; Takiguchi Y
Jpn J Clin Oncol; 2021 Mar; 51(3):363-370. PubMed ID: 33290513
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
[TBL] [Abstract][Full Text] [Related]
25. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.
Abu-Sbeih H; Ali FS; Wang Y
Curr Opin Gastroenterol; 2020 Jan; 36(1):25-32. PubMed ID: 31609734
[TBL] [Abstract][Full Text] [Related]
26. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.
Han X; Meng M; Zhang T; Wang J; Huang G; Ni Y; Li W; Dai J; Yang X; Ye X
J Cancer Res Ther; 2022 Sep; 18(5):1440-1443. PubMed ID: 36204895
[TBL] [Abstract][Full Text] [Related]
27. Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy.
Shieh AC; Guler E; Pfau D; Radzinsky E; Smith DA; Hoimes C; Ramaiya NH; Tirumani SH
Abdom Radiol (NY); 2020 Oct; 45(10):3028-3035. PubMed ID: 31754740
[TBL] [Abstract][Full Text] [Related]
28. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
[TBL] [Abstract][Full Text] [Related]
30. Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.
Singh BP; Marshall JL; He AR
Oncologist; 2020 Mar; 25(3):197-202. PubMed ID: 32162824
[TBL] [Abstract][Full Text] [Related]
31. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
32. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
33. Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.
Cassol CA; Owen D; Kendra K; Braga JR; Frankel WL; Arnold CA
Histopathology; 2020 Aug; 77(2):240-249. PubMed ID: 32298485
[TBL] [Abstract][Full Text] [Related]
34. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
[TBL] [Abstract][Full Text] [Related]
35. Checkpoint Inhibitor Colitis With Superimposed Clostridioides difficile Infection.
Mohammad AW; Kusnik A; Mostafa MR; Tan J; Strapko A
Cureus; 2023 Apr; 15(4):e37006. PubMed ID: 37139037
[TBL] [Abstract][Full Text] [Related]
36. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
37. [Colitis Suggested to be Related to Nivolumab in a Gastric Cancer Patient with a History of Ulcerative Colitis: A Case Report].
Ogawa T; Aimono Y; Saito Y; Yagisawa T; Iwayama T; Tamura A; Hirai S
Yakugaku Zasshi; 2024; 144(2):239-242. PubMed ID: 38296500
[TBL] [Abstract][Full Text] [Related]
38. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.
Yan Z; Yao ZH; Yao SN; Wang HY; Chu JF; Song M; Zhao S; Liu YY
Immunotherapy; 2020 Nov; 12(16):1161-1166. PubMed ID: 32814482
[No Abstract] [Full Text] [Related]
39. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.
Assarzadegan N; Montgomery E; Anders RA
Virchows Arch; 2018 Jan; 472(1):125-133. PubMed ID: 29143108
[TBL] [Abstract][Full Text] [Related]
40. Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitor-associated colitis.
Inoue S; Kono M; Fukuda H; Shimamoto Y; Nakagawa K; Ohmori M; Iwagami H; Matsuno K; Iwatsubo T; Nakahira H; Matsuura N; Shichijo S; Maekawa A; Kanesaka T; Yamamoto S; Takeuchi Y; Higashino K; Uedo N; Kitamura M; Nakatsuka S; Kunimasa K; Kumagai T; Isei T; Ishihara R
J Gastroenterol Hepatol; 2021 May; 36(5):1180-1186. PubMed ID: 32888202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
